Company intelligence
Mestag Therapeutics
New therapies for inflammatory disease and cancer by targeting fibroblast immunology
About Mestag Therapeutics
Mestag focuses on fibroblast-immune interactions to develop innovative new treatments for inflammatory disease and cancer. Through our unique understanding of fibroblast immunology, we are advancing a pipeline of first-in-class antibody programs and targets for new treatments. Backed by committed leading global investors, world-class founders and a highly experienced leadership team, Mestag offers an exciting, diverse and balanced place to work, with competitive benefits, generous vacation time and the room to grow and develop your career.
Verified activity
Signals from Mestag Therapeutics
4 published signals
Products & Services
Mestag Therapeutics reached an important milestone with the dosing of the first patient in the Phase 1 STARLYS trial for MST-0312.
Reported by Mestag Therapeutics
Partnerships
Mestag Therapeutics entered into a collaboration with the VIB Discovery Sciences lab on MST-0312, a FAP-targeted LTβR agonist bispecific antibody.
Reported by Mestag Therapeutics
Products & Services
Mestag Therapeutics is advancing a novel approach to cancer therapy with MST-0312, an FAP-targeted LTβR agonist bispecific antibody designed to induce tertiary lymphoid structures and high endothelial venules in solid tumors.
Reported by Mestag Therapeutics
Presence & Recognition
Mestag Therapeutics CEO Susan Hill and CMO Lindsey Rolfe will attend the 2026 Society for Immunotherapy of Cancer (SITC) EU Immuno-Oncology Drug Development Summit in Lausanne, Switzerland, on September 3-4.
Reported by Mestag Therapeutics